Pfizer announced problems with the production of a vaccine against COVID-19, writes Fox News .
Pfizer said it intends to release only half of the planned doses of the vaccine due to the fact that the expansion of the supply chain of raw materials for the vaccine took longer than expected. “It is also important to emphasize that the results of the clinical trials were later than originally planned,” a company spokeswoman said.
Pfizer and its German partner BioNTech SE were set to produce one hundred million vaccines by the end of the year. However, now the number of planned doses has been cut in half – to 50 million.
The company obtains raw materials from suppliers in the US and Europe, and expanding vaccine component production last month proved challenging. Then Pfizer was awaiting the results of drug tests. At the same time, it is not specified which components are missing for the production of the vaccine.
Earlier, the UK approved a coronavirus vaccine jointly produced by the American company Pfizer and by the German company BioNTech. The vaccine will be available across the UK starting next week. Pfizer – BioNTech vaccine has been approved by the Medicines and Healthcare Authority (MHRA).